Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus bevacizumab as salvage chemotherapy for unresectable colorectal cancer (SOAC1701)
jRCTs031180382Completed
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC). Primary endpoint: Progression-free survival. Started Sep 2019; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031180382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180382.